Trogenix is based in Edinburgh, United Kingdom. It has raised $111M in total funding. Latest round: Series A.
Trogenix funding overview
Trogenix is based in Edinburgh, United Kingdom. Trogenix has raised $111M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in January 2025. The round record for Trogenix runs through 2025; nothing later has been disclosed. Investors on record include 4BIO Capital, IQ Capital, Cancer Research Horizons, US National Brain Tumor Society, AIN Ventures, Old College Capital. 6 distinct backers are named across the disclosed rounds.
Trogenix at a glance
Total raised
$111M
Latest round
Series A
Latest round date
January 2025
Headquarters
Edinburgh, United Kingdom
Notable investors
4BIO Capital, IQ Capital, Cancer Research Horizons, US National Brain Tumor Society, AIN Ventures, Old College Capital
Frequently asked about Trogenix funding
How much has Trogenix raised?
Trogenix has raised $111M in total disclosed funding across the rounds on record.
Who has invested in Trogenix?
4BIO Capital, IQ Capital, Cancer Research Horizons, US National Brain Tumor Society, AIN Ventures, Old College Capital are named among the investors backing Trogenix.
What was the latest Trogenix funding round?
The most recent disclosed round is a Series A, announced in January 2025.
Where is Trogenix based?
Trogenix is based in Edinburgh, United Kingdom.
When did Trogenix last raise?
The last disclosed Trogenix round closed in January 2025 at Series A.
Totals shown for Trogenix aggregate every disclosed round on file. To see how that compares, browse the companies in Edinburgh and the investors behind them below.
